Spots Global Cancer Trial Database for Phase II Study of Dovitinib for FGFR1 Amplified Squamous Non-small Cell Lung Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Phase II Study of Dovitinib for FGFR1 Amplified Squamous Non-small Cell Lung Cancer
Official Title:
Study ID: NCT01861197
Conditions
Squamous NSCLC
Interventions
Dovitinib
Study Description
Brief Summary: Efficacy of Dovitinib for Squamous NSCLC.
Detailed Description:
Keywords
Eligibility
Minimum Age: 20 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Samsung Medical Center, Seoul, , Korea, Republic of
Contact Details
Name: Myung-Ju Ahn
Affiliation: Samsung Medical Center
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
